Phio Pharmaceuticals Shares Surge 60% on Virtual Roadshow and PH-762 Data

Introduction

Phio Pharmaceuticals Corp (NASDAQ: PHIO) is a U.S. clinical-stage biotechnology company focused on immuno-oncology. The company utilizes its proprietary INTASYL® self-delivering siRNA technology to target genes that enable tumors to evade the immune system. As of November 3, 2025, PHIO shares closed at $3.2813, with a 60.06% increase from the previous close and a trading volume of 12,619,957 shares.

Corporate Structure

Phio Pharmaceuticals was founded in 2012 and is headquartered in King of Prussia, Pennsylvania. The company was co-founded by Nobel Laureate Craig Mello and has been led by Executive Chair and Principal Executive Officer Robert Bitterman since September 2022. Phio operates as a public company and is involved in the biotechnology research sector, employing between 2 and 10 individuals.

Immuno-oncology by National Cancer Institute

Recent Developments and News

On October 28, 2025, Phio hosted a live virtual Non-Deal Roadshow in collaboration with Renmark Financial Communications, which included presentations on the INTASYL platform and the PH-762 clinical program. Robert Bitterman presented at the Life Sciences Future Conference on the same day, providing insights into early clinical data for PH-762 in cutaneous malignancies.

SEC filings include:

• A Form 8-K filed on October 31, 2025, reporting changes in executive appointments and other items.
• A Form 8-K filed on November 3, 2025, addressing material events and including updated financial statements.

Financial and Strategic Analysis

As of the third quarter of 2025, Phio reported approximately $10.78 million in cash and cash equivalents, with a trailing twelve-month net loss of $7.08 million and a diluted EPS of –$2.06. The company’s market capitalization was approximately $11.74 million, and it reported no debt. Phio has a beta of 0.95, and its shares have traded within a 52-week range of $0.9660 to $9.7900. Analysts projected a one-year target price of $14.00.

Phio is focusing its development efforts on two lead programs:

• PH-762, an siRNA compound that targets PD-1 in cutaneous squamous cell carcinoma, advanced melanoma, and Merkel cell carcinoma, which is currently undergoing a Phase 1 dose-escalation trial.
• PH-894, an INTASYL agent that silences BRD4, which is progressing through preclinical studies and shows dual mechanisms in T cells and tumor cells, with potential applications for viral infections.

Additionally, Phio has a partnership with AgonOx on combining PH-762 with double-positive tumor-infiltrating lymphocytes.

Market Position and Industry Context

Phio operates within the micro-cap segment of the RNAi and immuno-oncology sectors. Its INTASYL platform is designed for self-delivery without the need for lipid carriers, differentiating Phio from competitors that use lipid nanoparticles or GalNAc conjugation. Key competitors in the RNAi pipeline include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Dicerna Pharmaceuticals. In the immuno-oncology landscape, Phio is engaged in a rapidly evolving field where RNAi therapies are developing alongside checkpoint inhibitors and adoptive-cell treatments.

tl;dr

As of November 3, 2025, PHIO shares increased 60.06% to $3.2813 amid heavy trading. In late October 2025, Phio hosted a virtual roadshow and presented clinical data for PH-762 at the Life Sciences Future Conference. SEC Form 8-K filings on October 31 and November 3, 2025, reported executive changes and included updated financial exhibits. The Phase 1 trial of PH-762 in cutaneous malignancies is in progress, while PH-894 is advancing through preclinical development. Analysts have established a one-year price target of $14.00.